A Second Manufacturer Just Told Nevada Not to Use its Drugs for Executions

The state’s deputy solicitor general called the move “ironic.”

Hailshadow/Getty

Fight disinformation: Sign up for the free Mother Jones Daily newsletter and follow the news that matters.

Another pharmaceutical company doesn’t want Nevada to use its drug to execute Scott Dozier. On Monday, a district judge approved a motion filed by Hikma, the manufacturer of the powerful opioid fentanyl, to join the lawsuit filed by Alvogen, the maker of the controversial sedative midazolam. Midazolam has been blamed for several botched executions in the past and was going to be part of a three-drug combination used to execute Dozier. His scheduled execution in July was put on hold after Alvogen filed suit. 

Hikma is arguing that the company specifically told Nevada in 2016 that its drugs could not be used for an execution. Alvogen made similar claims in its lawsuit, accusing the state of secretly obtaining the drug despite the company’s warnings that it does not approve of the use of its drugs for lethal injections. The third component of Nevada’s three-drug protocol is a muscle paralyzer that medical professionals said could mask the inmate’s pain during an execution.

Dozier has been on death row since 2007 for the 2002 murder of Jeremiah Miller. Beginning in 2016, he gave up any effort to appeal his sentence, and maintained that he wanted to be put to death. Just hours before Dozier was set to die on July 11, a district judge issued a temporary restraining order blocking the state from using the midazolam. In response, Nevada filed a petition with the Nevada Supreme Court, asking that the decision that halted the execution be thrown out and accusing Alvogen of mounting a public relations campaign. “[Alvogen] filed this lawsuit to salvage its image and shift the blame to the State for Alvogen’s failure to impose the controls that it was touting to anti-death penalty advocates,” the petition says. The state Supreme Court is now considering the petition.

Nevada now has to contend with yet another manufacturer and in response leveled similarly harsh criticism for Hikma, implying that it was attempting to distract attention from a far bigger problem. The deputy solicitor general called it “ironic that the maker of fentanyl, which is at the center of the nation’s opioid crisis and is responsible for illegal overdoses every day is going to…claim reputational injury from being associated with a lawful execution.” 

But some states still plan to use these drugs. Carey Moore, who is set to die in Nebraska on August 14, will likely now be the first person executed with the powerful painkiller. The state intends to use the opioid in a four-drug protocol to execute the inmate, who shot and killed Maynard Helgeland and Reuel Van Ness five days apart in 1979. Nebraska has come under fire for refusing to disclose where its lethal injection drugs came from despite court orders to do so. 

Assuming that the drugs were manufactured by Pfizer, Independent Nebraska state Sen. Ernie Chambers, a long time anti-death penalty advocateurged the company to follow in Alvogen’s footsteps and sue the state in order to have the drugs returned and the execution halted. But the company said it had no records of Nebraska obtaining restricted drugs and was not going to file a lawsuit. “So where did the governor get his drugs?” Chambers wrote on Facebook after Pfizer declined to sue the state. “He’s not saying, and he’s refusing to obey the courts who have ordered him to share the information.”

AN IMPORTANT UPDATE

We’re falling behind our online fundraising goals and we can’t sustain coming up short on donations month after month. Perhaps you’ve heard? It is impossibly hard in the news business right now, with layoffs intensifying and fancy new startups and funding going kaput.

The crisis facing journalism and democracy isn’t going away anytime soon. And neither is Mother Jones, our readers, or our unique way of doing in-depth reporting that exists to bring about change.

Which is exactly why, despite the challenges we face, we just took a big gulp and joined forces with The Center for Investigative Reporting, a team of ace journalists who create the amazing podcast and public radio show Reveal.

If you can part with even just a few bucks, please help us pick up the pace of donations. We simply can’t afford to keep falling behind on our fundraising targets month after month.

Editor-in-Chief Clara Jeffery said it well to our team recently, and that team 100 percent includes readers like you who make it all possible: “This is a year to prove that we can pull off this merger, grow our audiences and impact, attract more funding and keep growing. More broadly, it’s a year when the very future of both journalism and democracy is on the line. We have to go for every important story, every reader/listener/viewer, and leave it all on the field. I’m very proud of all the hard work that’s gotten us to this moment, and confident that we can meet it.”

Let’s do this. If you can right now, please support Mother Jones and investigative journalism with an urgently needed donation today.

payment methods

AN IMPORTANT UPDATE

We’re falling behind our online fundraising goals and we can’t sustain coming up short on donations month after month. Perhaps you’ve heard? It is impossibly hard in the news business right now, with layoffs intensifying and fancy new startups and funding going kaput.

The crisis facing journalism and democracy isn’t going away anytime soon. And neither is Mother Jones, our readers, or our unique way of doing in-depth reporting that exists to bring about change.

Which is exactly why, despite the challenges we face, we just took a big gulp and joined forces with The Center for Investigative Reporting, a team of ace journalists who create the amazing podcast and public radio show Reveal.

If you can part with even just a few bucks, please help us pick up the pace of donations. We simply can’t afford to keep falling behind on our fundraising targets month after month.

Editor-in-Chief Clara Jeffery said it well to our team recently, and that team 100 percent includes readers like you who make it all possible: “This is a year to prove that we can pull off this merger, grow our audiences and impact, attract more funding and keep growing. More broadly, it’s a year when the very future of both journalism and democracy is on the line. We have to go for every important story, every reader/listener/viewer, and leave it all on the field. I’m very proud of all the hard work that’s gotten us to this moment, and confident that we can meet it.”

Let’s do this. If you can right now, please support Mother Jones and investigative journalism with an urgently needed donation today.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate